

P9850501

An Application Data Sheet was filed in reference to this application on May 19, 2006.

Page 1 of 2 Pages Original Substitute Supplemental Atty. Docket: ANDERSEN8

**COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR
UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET
(37 CFR 1.76)**

TITLE OF THE INVENTION		PROTEINS BELONGING TO THE BCL-2 FAMILY AND FRAGMENTS THEREOF, AND THEIR USE IN CANCER PATIENTS
<p>This declaration is directed to:</p> <p><input type="checkbox"/> the attached application;</p> <p><input type="checkbox"/> the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appln. No. _____ *; or</p> <p><input checked="" type="checkbox"/> the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, <u>PCT/DK2004/000799</u>; filed November 18, 2004, entry requested on May 19, 2006; national stage application received U.S. Appln. No. 10/580,016; §371/§102(e) date _____ * (* if known)</p> <p><input type="checkbox"/> as amended on _____ (if applicable).</p>		
<p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p>		
<p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p>		
<p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p>		
<p>All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p>		
<p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p>		
<p style="text-align: center;">All of the practitioners associated with Customer Number 001444</p>		
<p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p>		
<p style="text-align: center;">BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197</p>		
<p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from HOIBERG A/S as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p>		
<p>FULL NAME OF INVENTOR(S)</p>		
<p>Inventor one: <u>Mads Hald ANDERSEN</u> Date: <u>2/2/06</u></p>		
<p>Signature: <u>Mads Hald</u> Citizen of: <u>Denmark</u></p>		
<p>Inventor two: <u>Per Thor STRATEN</u> Date: <u>01/07/06</u></p>		
<p>Signature: <u>Per Thor Straten</u> Citizen of: <u>Denmark</u></p>		

Title: PROTEINS BELONGING TO THE BCL-2 FAMILY AND FRAGMENTS THEREOF, AND THEIR USE IN CANCER PATIENTS

U.S. Application filed _____, Serial No. 10/580,016

PCT Application filed November 18, 2004, Serial No. PCT/DK2004/000799

Inventor three: _____	Date: _____
Signature: _____	Citizen of: _____
Inventor four: _____	Date: _____
Signature: _____	Citizen of: _____
Inventor five: _____	Date: _____
Signature: _____	Citizen of: _____
[] Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.	

All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors.

Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).